Patel, Rima http://orcid.org/0000-0003-3486-3085
Li, Zhiqiang
Zimmerman, Brittney S.
Fink, Marc Y.
Wells, Jason D.
Zhou, Xiang
Ayers, Kristin
Redfern, Arielle
Newman, Scott
Schadt, Eric
Oh, William K.
Chen, Rong
Tiersten, Amy
Article History
Received: 9 September 2021
Accepted: 29 December 2021
First Online: 10 January 2022
Declarations
:
: R.P., B.S.Z., and A.T. report no conflicts of interest. Z.L., M.Y.F., J.D.W., X.Z., and A.R. report being employees of Sema4. K.A., S.N., and R.C. report being employees of Sema4 and holding company stock/stock options. E.S. reports being Chief Executive Officer and board member for Sema4 and on the scientific advisory board for Berg Pharma. W.K.O. reports serving as a consultant to Astellas, Astra-Zeneca, Bayer, Janssen, Pfizer and Sanofi. He also serves as Chief Medical Science Officer for Sema4.
: This study was approved by the Institutional Review Board at the Mount Sinai Health System (STUDY-20-02162).
: Waiver for consent for this retrospective study was obtained from the Institutional Review Board at the Mount Sinai Health System.
: All authors have reviewed this version of the manuscript and provided consent for publication.